Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Bajetta

Showing results (111-120 of 212) with videos related to

Pageof 22
Sort By:
Journal of Chemotherapy (Florence, Italy)|April 1, 2006
Capecitabine chemoradiation for rectal cancer after curative surgeryE Bajetta, E Beretta, M Di Bartolomeo, et al.
Tumori|February 28, 1994
Ovarian function suppression with the gonadotrophin-releasing hormone (GnRH) analogue goserelin in premenopausal advanced breast cancerE Bajetta, L Celio, N Zilembo, et al.
Breast Cancer Research and Treatment|June 1, 1995
Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I.T.M.O. Group. Italian Trials in Medical OncologyA Di Leo, L Ferrari, E Bajetta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 22, 2009
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II studyS Siena, L Crinò, M Danova, et al.
Oncology|January 1, 1996
Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patientsM Di Bartolomeo, E Bajetta, L Somma, et al.
Cancer|July 1, 1996
A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinomaA Di Leo, E Bajetta, L Ferrari, et al.
International Journal of Oncology|May 12, 2011
Reliability of immunoradiometric assays for sex-hormone binding globulin, androstenedione, 17-Beta estradiol and tumor-markers cea and cb15.3 to assess the biological response of megestrol-acetate treatment in patients with advanced breast-cancerC Botti, A Bogni, E Seregni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2013
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trialG Procopio, E Verzoni, S Bracarda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2003
Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancerE Bajetta, L Celio, R Buzzoni, et al.
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)|August 10, 2000
New clinical trials for the treatment of neuroendocrine tumorsE Bajetta, E Bichisao, S Artale, et al.
Pageof 22

Showing results (111-120 of 212) with videos related to

Sort By:
Pageof 22
Journal of Chemotherapy (Florence, Italy)|April 1, 2006
Capecitabine chemoradiation for rectal cancer after curative surgeryE Bajetta, E Beretta, M Di Bartolomeo, et al.
Tumori|February 28, 1994
Ovarian function suppression with the gonadotrophin-releasing hormone (GnRH) analogue goserelin in premenopausal advanced breast cancerE Bajetta, L Celio, N Zilembo, et al.
Breast Cancer Research and Treatment|June 1, 1995
Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I.T.M.O. Group. Italian Trials in Medical OncologyA Di Leo, L Ferrari, E Bajetta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 22, 2009
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II studyS Siena, L Crinò, M Danova, et al.
Oncology|January 1, 1996
Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patientsM Di Bartolomeo, E Bajetta, L Somma, et al.
Cancer|July 1, 1996
A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinomaA Di Leo, E Bajetta, L Ferrari, et al.
International Journal of Oncology|May 12, 2011
Reliability of immunoradiometric assays for sex-hormone binding globulin, androstenedione, 17-Beta estradiol and tumor-markers cea and cb15.3 to assess the biological response of megestrol-acetate treatment in patients with advanced breast-cancerC Botti, A Bogni, E Seregni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2013
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trialG Procopio, E Verzoni, S Bracarda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2003
Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancerE Bajetta, L Celio, R Buzzoni, et al.
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)|August 10, 2000
New clinical trials for the treatment of neuroendocrine tumorsE Bajetta, E Bichisao, S Artale, et al.
Pageof 22